Environmental responsibilities

At Oncopeptides we continually strive to minimize the environmental impact of our own operations and those of our suppliers. Our Environmental Policy, adopted in 2017 and which all employees are expected to follow, states that environmental impact should be part of the company’s decision-making processes and that our products should not consume more natural resources than necessary. We strive to prevent pollution, reduce carbon emissions, and work actively to minimize waste and energy and water use.

We will continue to improve the transparency of our environmental initiatives and performance and encourage our suppliers and contractors to align with our environmental standards and transparency through contractual obligations and supplier agreements. At a company level and on an individual level, we will continue to make decisions that minimize our environmental impact.

Our approach to environmental responsibilities

The need for action to reverse damage to the climate is of the utmost urgency and we need to accelerate our efforts to reduce environmental impacts in response. We also know that environmental issues are likely to become increasingly commercially important and a potential differentiator.

In our supply chain, we continue to work with Contract Manufacturing Organizations (CMOs) on their management of environmental impacts and screen suppliers before working with them. Therefore, we focus on our suppliers and select CMOs and other vendors based in countries where regulatory standards are similar to those in Sweden.

We limit the use of flights where possible, and employees are encouraged to ensure that trips have multiple purposes and are absolutely necessary. On a local level, employees are encouraged to take public transport where possible.

Environmental issues in our operations

Oncopeptides operates in a highly regulated space, where environmental impacts are tightly controlled. However, we continue to improve our understanding of our environmental footprint and thereby reduce it further. In 2020, we took steps towards establishing key performance indicators and making the reduction of environmental impacts an integral component of our decision-making processes.

Our state-of-the-art laboratory in Solna, which became fully operational in September 2020, is effectively a closed system with virtually no impact on the local environment. As with all modern-day labs in highly regulated geographies such as the EU, chemical handling and disposal and waste disposal is tightly controlled. Much of the company’s environmental impact is embedded in our products. Therefore, we focus on our suppliers and select CMOs and other vendors based in countries where regulatory standards are high. Our safety representative conducts checks at our Solna facility on a regular basis to ensure the safety of employees and that environmental standards are upheld.

We conduct clinical studies at approximately 130 hospitals in 25 countries and our drugs are of course transported, which causes carbon emissions. We therefore include environmental impact in decisions related to shipping and where possible select companies that are more environmentally aware and transparent.

Due to the rapid growth in headcount, we have decided to adopt a more flexible approach to working from home to enable us to continue to use our existing office space. This also reduces emissions in terms of people travelling to and from the office.